CNCR

Loncar Cancer Immunotherapy ETF
N/A

N/A
  • Overview
  • Efficiency
  • Tradability
  • Fit

CNCR Fund Description

This fund tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.

CNCR Factset Analytics Insight

CNCR takes a novel approach to niche coverage within the health care sector. It provides equal- weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting the securities draws attention to smaller companies with room to grow. While it’s still too soon to access performance, this fund provides a unique option for investors placing a highly specialized bet on this space.

CNCR MSCI ESG Analytics Insight

The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of January 15, 2018 the Loncar Cancer Immunotherapy ETF MSCI ESG Fund Quality Score is 4.10 out of 10.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. CNCR ranks in the 8th percentile within its peer group and in the 10th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
COMPARE
RESET
Select ETFs to compare their performance:

CNCR Top 10 Countries

CNCR Top 10 Sectors

CNCR Top 10 Holdings View All

CNCR Summary Data

Loncar
10/13/15
Open-Ended Fund
0.79%
$41.41M
$466.64K
0.30%

CNCR Portfolio Data

$20.98B
-7.74
3.85
1.36%
N/A
30

CNCR Index Data

Equal
Market Cap
Thomson Reuters US Biotechnology & Medical Research

Related ETFs to CNCR

XBI, FBT, BBP, BBC, IBB
Total Return
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max

CNCR Portfolio Management

0.79%
--
--
--

CNCR Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

CNCR Fund Structure

Open-Ended Fund
No
No
No Policy
N/A
N/A
High
Daily
Bats Book Viewer
TOP OF BOOK
SHARES/SIZEPRICE
ASKS----
----
----
----
----
BIDS----
----
----
----
----
LAST 10 TRADES
TIMEPRICESHARES
11:38:3825.44257
11:38:3825.44100
11:38:3625.44100
11:00:4725.65100
11:00:1825.70122
10:59:5625.71100
10:59:5625.71100
10:15:1225.99200
10:15:1225.99100
10:15:1025.99100
Bats BZX Real-time Quote - 17:23:23
Daily Spread
Premium/Discount
Volume

CNCR Factset Analytics Block Liquidity

As of 01/16/18
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of CNCR. CNCR is rated a 3 out of 5.

CNCR Tradability

19,247
$466.64K
13,610
$336.53K
0.30%
$0.07
0.09%
1.17% / -0.64%
None
100.00%
50,000
0.27
0.01%
0.87%
--
$25.66
3

CNCR Geographic Exposure

CNCRSegment Benchmark
100.00% 91.14%
-- 3.09%
-- 3.02%
-- 2.75%

CNCRSegment Benchmark
100.00% 91.14%
-- 8.86%
0.00% / 0.00% 0.00% / 0.00%

CNCR Performance Statistics

0.61
1.25
0.98
1.22
1.08%
Thomson Reuters US Biotechnology & Medical Research

CNCR MSCI ESG Ratings

4.10 / 10
8.33
10.20
2.32%
5.31%
24.70

CNCR BENCHMARK COMPARISON

    CNCR
    30 Holdings
    Segment Benchmark
    122 Constituents
    Shared Holdings
    15 (Count)
     
    9.23% (Weight)
CNCRSegment Benchmark
51.30% 16.80%
30.02% 17.17%
15.75% 36.71%
2.94% 29.32%
164.16 -7.74
0.77% 0.47%